Long-term, heavy smoking doubles the risk of more aggressive prostate cancer in middle-aged men

July 14, 2003

SEATTLE - Middle-aged men who are long-term, heavy smokers face twice the risk of developing more aggressive forms of prostate cancer than men who have never smoked, according to new findings from Fred Hutchinson Cancer Research Center that appears in the July issue of Cancer Epidemiology, Biomarkers and Prevention, a publication of the American Association for Cancer Research.

Specifically, men under age 65 with a history of 40 or more "pack-years" (those who smoke a pack a day for 40 years or two packs a day for 20 years) of cigarette smoking face a 100 percent increased risk - or double the risk - of developing more aggressive forms of the disease as compared to nonsmokers, according to senior author Janet L. Stanford, Ph.D., and colleagues in Fred Hutchinson's Public Health Sciences Division. Such men with heavy smoking exposure also face a 60 percent increased risk of prostate cancer overall relative to nonsmokers. Compared to nonsmokers, current smokers experienced a 40 percent increase in the risk of prostate cancer.

Researchers from the University of Washington School of Medicine also collaborated on the study, which was funded by the National Cancer Institute.

"This study provides additional evidence that supports a role for smoking as a risk factor for prostate cancer and confirms recent findings that suggest smoking is an even stronger risk factor for more life-threatening forms of prostate cancer," said Stanford, director of Fred Hutchinson's Prostate Cancer Research Program.

Previously, research results regarding smoking and prostate cancer have been mixed, but these results, together with recent findings from investigators at Johns Hopkins University and Harvard University, provide cumulative evidence that smoking - in particular high-dose, long-term cigarette exposure - is an important risk factor for prostate cancer, said Stanford, also a professor of epidemiology at the University of Washington School of Public Health and Community Medicine.

"From a public-health perspective, I think we now have enough evidence to suggest that prostate cancer should be added to the long list of malignancies in which smoking plays a role," she said. Other smoking-related cancers include those of the lung, bladder, cervix, esophagus and kidney.

The study involved more than 1,450 Seattle-area men, ages 40 to 64. Half had a history of prostate cancer (diagnosed between 1993 and 1996) and the other half, which did not have a history of prostate cancer, served as a comparison group. Participants completed detailed in-person interviews that assessed a variety of factors, from smoking and alcohol consumption to diet and occupational history.

One of the study's strengths is that it focused on younger men who have a lower overall incidence of prostate cancer, which may have enhanced the researchers' ability to tease out the effects of specific risk factors.

"The contribution of smoking to prostate cancer may have been easier to detect in men under 65, who are at lower absolute risk of the disease, than in older men, in whom the cumulative effects of numerous risk factors may cloud the picture," Stanford said.

Another strength of the study is that it assessed other lifestyle variables - from prostate-cancer screening history to dietary intake - factors which, if unaccounted for during data analysis, might have biased the results.

Smoking may promote prostate cancer through several mechanisms. One is that it can increase the amount of circulating androgens, which fuel the growth of normal and malignant prostate cells.

"Cigarette smoking appears to alter a man's hormonal milieu by tilting the scale toward a hormonal environment that may be conducive to tumor growth," Stanford said.

Another theory is related to tobacco as a source of cadmium, a heavy metal that has been linked to prostate cancer in several occupational-health studies. This known human carcinogen inhibits DNA repair, which allows cancer cells to mutate and multiply.

"Cadmium has been shown to be concentrated in the prostate, so this may be one chemical exposure from cigarette smoking that could have an adverse biological effect on the prostate," Stanford said.

One positive finding, however, is that while the relative risk of developing prostate cancer increases with the number of pack-years smoked, this risk declines to near that of nonsmokers within about 10 years of quitting, Stanford said.

"When men stop smoking, within a decade their risk of prostate cancer returns to a level that is not substantially different from nonsmokers, so for most men, it's not too late to quit. There are few environmental risk factors for prostate cancer that have been identified, but here's one way that men can take action to reduce their risk," she said.
-end-
Note for media: To arrange an interview or obtain a copy of the paper "Cigarette smoking and risk of prostate cancer in middle-aged men" by Stanford and colleagues, please contact Kristen Woodward in Fred Hutchinson Media Relations, 206-667-5095 or kwoodwar@fhcrc.org.

The Fred Hutchinson Cancer Research Center, home of two Nobel Prize laureates, is an independent, nonprofit research institution dedicated to the development and advancement of biomedical research to eliminate cancer and other potentially fatal diseases. Fred Hutchinson receives more funding from the National Institutes of Health than any other independent U.S. research center. Recognized internationally for its pioneering work in bone-marrow transplantation, the center's four scientific divisions collaborate to form a unique environment for conducting basic and applied science. Fred Hutchinson, in collaboration with its clinical partners, the University of Washington Academic Medical Center and Children's Hospital and Regional Medical Center, is the only National Cancer Institute-designated comprehensive cancer center in the Pacific Northwest and is one of 39 nationwide. For more information, visit the center's Web site at www.fhcrc.org.

Advancing Knowledge, Saving Lives

SIDEBAR

IN ADDITION TO NOT SMOKING, WHAT ELSE CAN A MAN DO TO REDUCE HIS RISK OF PROSTATE CANCER?

In addition to not smoking, what else can a man do to reduce his risk of prostate cancer? Janet Stanford, Ph.D., director of the Prostate Cancer Research Program at Fred Hutchinson Cancer Research Center, suggests the following lifestyle changes based on research conducted at Fred Hutchinson and elsewhere:

Fred Hutchinson Cancer Research Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.